Search research articles
Contact Us
Filters
Showing results (411-420 of 505) with videos related to
Page
of 51
Sort By:
American Journal of Respiratory and Critical Care Medicine
|
June 26, 2020
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
MeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
Plos One
|
September 30, 2016
Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD
Martin A Bewley, Kylie B R Belchamber, Kirandeep K Chana, et al.
Vaccines
|
June 27, 2024
Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
Charlotte Davis, Dave Singh, Katie Anderson, et al.
The Journal of Allergy and Clinical Immunology
|
January 17, 2017
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients
Philip E Silkoff, Michel Laviolette, Dave Singh, et al.
Respiratory Research
|
April 29, 2021
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
Dave Singh, Gerard J Criner, Mark T Dransfield, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 25, 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
David B Price, William Henley, José Eduardo Delfini Cançado, et al.
Chest
|
April 3, 2023
Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial
Dermot A Linden, Hong Guo-Parke, Michael C McKelvey, et al.
The Lancet. Respiratory Medicine
|
July 12, 2025
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial
Stephanie A Christenson, Nicola A Hanania, Surya P Bhatt, et al.
ERJ Open Research
|
February 22, 2020
ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly
Lies Lahousse, Thomas Bahmer, Sara Cuevas-Ocaña, et al.
Chest
|
February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS
Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Page
of 51
Search research articles
Search
Showing results (411-420 of 505) with videos related to
Sort By:
Page
of 51
American Journal of Respiratory and Critical Care Medicine
|
June 26, 2020
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
MeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
Plos One
|
September 30, 2016
Differential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD
Martin A Bewley, Kylie B R Belchamber, Kirandeep K Chana, et al.
Vaccines
|
June 27, 2024
Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
Charlotte Davis, Dave Singh, Katie Anderson, et al.
The Journal of Allergy and Clinical Immunology
|
January 17, 2017
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients
Philip E Silkoff, Michel Laviolette, Dave Singh, et al.
Respiratory Research
|
April 29, 2021
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
Dave Singh, Gerard J Criner, Mark T Dransfield, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
February 25, 2022
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone
David B Price, William Henley, José Eduardo Delfini Cançado, et al.
Chest
|
April 3, 2023
Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial
Dermot A Linden, Hong Guo-Parke, Michael C McKelvey, et al.
The Lancet. Respiratory Medicine
|
July 12, 2025
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial
Stephanie A Christenson, Nicola A Hanania, Surya P Bhatt, et al.
ERJ Open Research
|
February 22, 2020
ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly
Lies Lahousse, Thomas Bahmer, Sara Cuevas-Ocaña, et al.
Chest
|
February 2, 2025
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS
Surya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
Page
of 51